Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Inflammation01:38

Inflammation

Overview
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Asialoglycoprotein receptor subunit Asgr1a loss results in attenuated cholesterol absorption in zebrafish fed a western diet.

The Journal of biological chemistry·2026
Same author

Are we underestimating the benefits of lipid-lowering therapies?

Pharmacological reviews·2026
Same author

Bempedoic acid for prevention of atherosclerotic cardiovascular disease: from trials to clinical practice.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2026
Same author

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes.

British journal of pharmacology·2026
Same author

Homozygous familial hypercholesterolemia: Will new LDL-C-lowering drugs replace lipoprotein apheresis?

European journal of preventive cardiology·2026
Same author

The role of bempedoic acid in the management of dyslipidaemia in people with diabetes: an expert opinion of Italian diabetologists.

Cardiovascular diabetology·2026

Related Experiment Video

Updated: May 8, 2026

Imaging and Analysis of Oil Red O-Stained Whole Aorta Lesions in an Aneurysm Hyperlipidemia Mouse Model
07:57

Imaging and Analysis of Oil Red O-Stained Whole Aorta Lesions in an Aneurysm Hyperlipidemia Mouse Model

Published on: May 2, 2022

LOX-1, OxLDL, and atherosclerosis.

Angela Pirillo1, Giuseppe Danilo Norata, Alberico Luigi Catapano

  • 1Center for the Study of Atherosclerosis, E. Bassini Hospital, 20092 Cinisello Balsamo, Italy. angela.pirillo@guest.unimi.it

Mediators of Inflammation
|August 13, 2013
PubMed
Summary

Oxidized low-density lipoprotein (OxLDL) drives atherosclerosis. The lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is a key mediator, and its inhibition is a potential therapeutic strategy.

More Related Videos

Quantification of Atherosclerosis in Mice
06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

Related Experiment Videos

Last Updated: May 8, 2026

Imaging and Analysis of Oil Red O-Stained Whole Aorta Lesions in an Aneurysm Hyperlipidemia Mouse Model
07:57

Imaging and Analysis of Oil Red O-Stained Whole Aorta Lesions in an Aneurysm Hyperlipidemia Mouse Model

Published on: May 2, 2022

Quantification of Atherosclerosis in Mice
06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Atherosclerosis Research

Background:

  • Oxidized low-density lipoprotein (OxLDL) is a critical factor in atherosclerotic plaque development.
  • Vascular cells, including endothelial cells, macrophages, and smooth muscle cells, express scavenger receptors for OxLDL.
  • The lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is the primary endothelial receptor for OxLDL and is upregulated in atherosclerotic lesions.

Purpose of the Study:

  • To elucidate the role of LOX-1 in OxLDL-mediated atherogenesis.
  • To investigate the impact of LOX-1 expression levels on atherosclerotic lesion formation and inflammation.
  • To explore the therapeutic potential of targeting the OxLDL-LOX-1 pathway.

Main Methods:

  • Review of existing literature on OxLDL, LOX-1, and atherosclerosis.
  • Analysis of data from animal models (LOX-1 knockout and overexpressing mice).
  • Examination of human genetic studies linking LOX-1 polymorphisms to myocardial infarction.

Main Results:

  • LOX-1 knockout mice showed reduced atherosclerotic lesion thickness and inflammation.
  • LOX-1 overexpressing mice exhibited accelerated lesion formation and increased inflammation.
  • Human genetic studies associated LOX-1 polymorphisms with increased myocardial infarction risk.

Conclusions:

  • LOX-1 plays a pivotal role in promoting atherosclerosis by mediating the proatherogenic effects of OxLDL.
  • Targeting LOX-1 presents a promising therapeutic avenue for managing atherosclerosis.
  • Inhibition of the OxLDL-LOX-1 interaction could mitigate cardiovascular disease progression.